http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112494654-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 |
filingDate | 2020-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-112494654-B |
titleOfInvention | Pharmaceutical composition comprising LncRNA HCG18 inhibitor and use thereof |
abstract | The present invention provides pharmaceutical compositions comprising LncRNA HCG18 inhibitors. The present invention fully reveals the function of LncRNA HCG18 in prostate cancer cells and the target genes regulated by it, and clarifies the new mechanism of LncRNA HCG18 regulating prostate cancer. The present invention conducts in-depth research on the specific mechanism of LncRNA HCG18 in the process of prostate cancer occurrence, development, migration, invasion, apoptosis, etc. It is determined that miR-23a is the target gene of LncRNA HCG18, and the effect of miR-23a on the downstream of LncRNA HCG18 is determined. The effect of protein GLS and LDH. In addition, the present invention conducts in-depth research on the mechanism by which LncRNA HCG18 and miR-23a participate in regulating the energy metabolism of prostate cancer cells, clarifies the mechanism of the occurrence and development of prostate cancer, and provides insights for disease progression and targeted therapy of prostate cancer. Sufficient theoretical basis provides new ideas for later-stage related drug development, clinical diagnosis and treatment, and has great social significance and market prospects. |
priorityDate | 2020-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 250.